Cancers related to immunodeficiencies: Update and perspectives

Frontiers in Immunology

Volumn 7, Issue SEP, 2016, Pages

  Mortaz, Esmaeil ^a,b,c   Tabarsi, Payam ^d   Mansouri, Davod ^b   Khosravi, Adnan ^b   Garssen, Johan ^c,e   Velayati, Aliakbar ^f   Adcock, Ian M ^g  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UTRECHT UNIVERSITY   (Netherlands)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e DANONE NUTRICIA RESEARCH   (Netherlands)

^f SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Malignancy; Primary immunodeficiency

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 4; PROTEIN KINASE TYK2; STAT3 PROTEIN; TRANSCRIPTION FACTOR GATA 2;

ATAXIA TELANGIECTASIA; CARCINOGENESIS; CELLULAR IMMUNITY; CHRONIC LUNG DISEASE; DISORDERS OF DNA SYNTHESIS AND REPAIR; GENE MUTATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; HUMORAL IMMUNITY; HYPER IGE SYNDROME; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; NEOPLASM; NIJMEGEN BREAKAGE SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; TRANSPLANTATION; WISKOTT ALDRICH SYNDROME; X LINKED AGAMMAGLOBULINEMIA;

EID: 84992143314     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00365     Document Type: Review

References (184)

1. Page AR, Hansen AE, Good RA. Occurrence of leukemia and lymphoma in patients with agammaglobulinemia. Blood (1963) 21(2):197-206.
2. Boder E, Sedgwick RP. Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics (1958) 21:526-54.
3. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. Cancer (1971) 28:89-98. doi: 10.1002/1097-0142(197107)28:1<89::AID-CNCR2820280117>3.0.CO;2-Q
4. Waldmantn A, Strober W, Blaeser M. Immunodeficiency disease and malignancy: various immunologic deficiencies of man and the role of immune processes in the control of malignant disease. Ann Intern Med (1972) 77:605-28. doi:10.7326/0003-4819-77-4-605
5. Sedgwick RP, Boder E. Ataxia-telangiectasia. In: Vinken PJ, Bruyn GW, editors. Handbook of Clinical Neurology. Amsterdam: North-Holland (1972). p. 267-339.
6. Kersey JH, Spectorb D, Good RA. Immunodeficiency and cancer. In: Weinhouse S, Klein G, editors. Advances in Cancer Research (Vol. 18), New York: Academic Press (1973). p. 75-8.
7. Madkaikar M, Mishra A, Ghosh K. Diagnostic approach to primary immune deficiency disorders. Indian Pediatr (2013) 50:579-86. doi:10.1007/s13312-013-0171-4
8. Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol (2007) 120:776-94. doi:10.1016/j.jaci.2007.08.053
9. Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol (2014) 5:162. doi:10.3389/fimmu.2014.00162
10. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. J Clin Immunol (2015) 35:696-726. doi:10.1007/s10875-015-0201-1
11. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol (2007) 27:497-502. doi:10.1007/s10875-007-9103-1
12. Mueller BU, Pizzo PA. Cancer in children with primary or secondary immunodeficiencies. J Pediatr (1996) 126:1-10. doi:10.1016/S0022-3476(95)70491-4
13. Salavoura K, Kolialexi A, Tsangaris G, Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res (2008) 28(2B):1263-9.
14. Tabarsi P, Marjani M, Mansouri N, Farnia P, Boisson-Dupuis S, Bustamante J, et al. Lethal tuberculosis in a previously healthy adult with IL-12 receptor deficiency. J Clin Immunol (2011) 31:537-9. doi:10.1007/s10875-011-9523-9
15. Mansouri D, Adimi P, Mirsaedi M, Mansouri N, Tabarsi P, Amiri M, et al. Primary immune deficiencies presenting in adults: seven years of experience from Iran. J Clin Immunol (2005) 25:385-91. doi:10.1007/s10875-005-4124-0
16. McCusker C, Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol (2011) 7:S11. doi:10.1186/1710-1492-7-S1-S11
17. Andrews T, Sullivan KE. Infections in patients with inherited defects in phagocytic function. Clin Microbiol Rev (2003) 16:597-621. doi:10.1128/CMR.16.4.597-621.2003
18. Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev (2009) 22:396-414. doi:10.1128/CMR.00001-09
19. Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol (2011) 2:54. doi:10.3389/fimmu.2011.00054
20. Slatter MA, Gennery AR. Clinical immunology review series: an approach to the patient with recurrent infections in childhood. Clin Exp Immunol (2008) 152:389-96. doi:10.1111/j.1365-2249.2008.03641.x
21. Bonilla FA, Geha RS. Primary immunodeficiency diseases. J Allergy Clin Immunol (2003) 111:571-81. doi:10.1067/mai.2003.86
22. Ballow M. Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol (2002) 109:581-91. doi:10.1067/mai.2002.122466
23. Casanova JL, Fieschi C, Zhang SY, Abel L. Revisiting human primary immunodeficiencies. J Intern Med (2008) 264:115-27. doi:10.1111/j.1365-2796.2008.01971.x
24. Corthay A. Does the immune system naturally protect against cancer? Front Immunol (2014) 5:197. doi:10.3389/fimmu.2014.00197
25. Kinlen LJ, Webster AD, Bird AG, Haile R, Peto J, Soothill JF, et al. Prospective study of cancer in patients with hypogammaglobulinemia. Lancet (1985) 1:263-6. doi:10.1016/S0140-6736(85)91037-2
26. van der Meer JW, Weening RS, Schellekens PT, van Munster IP, Nagengast FM. Colorectal cancer in patients with X-linked agammaglobulinemia. Lancet (1993) 341:1439-40. doi:10.1016/0140-6736(93)90883-I
27. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol (1999) 92:34-48. doi:10.1006/clim.1999.4725
28. Saiki O, Ralph P, Cunningham-Rundles C, Good RA. Three distinct stages of B-cell defects in common varied immunodeficiency. Proc Natl Acad Sci U S A (1982) 79:6008-12. doi:10.1073/pnas.79.19.6008
29. Mellemkjaer L, Hammarstrom L, Andersen V, Yuen J, Heilmann C, Barington T, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol (2002) 130:495-500. doi:10.1046/j.1365-2249.2002.02004.x
30. Mohammadinejad P, Aghamohammadi A, Abolhassani H, Sadaghiani MS, Abdollahzade S, Sadeghi B, et al. Pediatric patients with common variable immunodeficiency: long-term follow-up. J Investig Allergol Clin Immunol (2012) 22(3):208-14.
31. Ogershok PR, Hogan MB, Welch JE, Corder WT, Wilson NW. Spectrum of illness in pediatric common variable immunodeficiency. Ann Allergy Asthma Immunol (2006) 97:653-6. doi:10.1016/S1081-1206(10)61096-4
32. Quinti I, Soresina A, Spadaro G, Martino S, Donnanno S, Agostini C, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol (2007) 27:308-16. doi:10.1007/s10875-007-9075-1
33. Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev (2006) 5:156-9. doi:10.1016/j.autrev.2005.10.002
34. Brandt D, Gershwin ME. Common variable immune deficiency and autoimmunity. Autoimmun Rev (2006) 5:465-70. doi:10.1016/j.autrev.2006.03.010
35. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood (2012) 119:1650-7. doi:10.1182/blood-2011-09-377945
36. Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet (2008) 372:489-502. doi:10.1016/S0140-6736(08)61199-X
37. Aghamohammadi A, Farhoudi A, Moin M, Rezaei N, Kouhi A, Pourpak Z, et al. Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency. Clin Diagn Lab Immunol (2005) 12(7):825-32.
38. Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood (2008) 112:277-86. doi:10.1182/blood-2007-11-124545
39. Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, Lieberman P. Incidence of cancer in 98 patients with common varied immunodeficiency. J Clin Immunol (1987) 7:294-9. doi:10.1007/BF00915550
40. Dhalla F, Silva SP, Lucas M, Travis S, Chapel H. Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme. Clin Exp Immunol (2011) 165:1-7. doi:10.1111/j.1365-2249.2011.04384.x
41. Vajdic CM, Mao L, van Leeuwen MT, Kirkpatrick P, Grulich AE, Riminton S. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood (2010) 116:1228-34. doi:10.1182/blood-2010-03-272351
42. Baron-Ruiz I, Martin-Mateos MA, Plaza-Martin AM, Giner-Munoz MT, Piquer M. Lymphoma as presentation of common variable immunodeficiency. Allergol Immunopathol (2009) 37:51-3. doi:10.1016/S0301-0546(09)70254-X
43. Chua I, Quinti I, Grimbacher B. Lymphoma in common variable immunodeficiency: interplay between immune dysregulation, infection and genetics. Curr Opin Hematol (2008) 15:368-74. doi:10.1097/MOH.0b013e328302c7b6
44. Aghamohammadi A, Parvaneh N, Tirgari F, Mahjoob F, Movahedi M, Gharagozlou M, et al. Lymphoma of mucosa-associated lymphoid tissue in common variable immunodeficiency. Leuk Lymphoma (2006) 47:343-6. doi:10.1080/10428190500285285
45. Cunningham-Rundles C, Cooper DL, Duffy TP, Strauchen J. Lymphomas of mucosal-associated lymphoid tissue in common variable immunodeficiency. Am J Hematol (2002) 69:171-8. doi:10.1002/ajh.10050
46. Davis SD, Schaller J, Wedgwood RJ. Job's syndrome. Recurrent, "cold" staphylococcal abscesses. Lancet (1966) 1:1013-5. doi:10.1016/S0140-6736(66)90119-X
47. Buckley RH, Wray BB, Belmaker EZ. Extreme hyper immunoglobulinemia E and undue susceptibility to infection. Pediatrics (1972) 49:59-70.
48. Buckley RH. The hyper IgE syndrome. Clin Rev Allergy Immunol (2001) 20:139-54. doi:10.1385/CRIAI:20:1:139
49. Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore) (2012) 91:1-19. doi:10.1097/MD.0b013e31825f95b9
50. Milner JD. Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature (2008) 452:773-6. doi:10.1038/nature06764
51. Beaucoudrey LD, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh M, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17 producing T cells. J Exp Med (2008) 205:1543-50. doi:10.1084/jem.20080321
52. Jiao H, Tóth B, Erdos M, Fransson I, Rákóczi E, Balogh I, et al. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. Mol Immunol (2008) 46:202-6. doi:10.1016/j.molimm.2008.07.001
53. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature (2007) 448:1058-62. doi:10.1038/nature06096
54. Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, Carey JC, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol (2008) 122:181-7. doi:10.1016/j.jaci.2008.04.037
55. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med (2008) 205:1551-7. doi:10.1084/jem.20080218
56. Siegel AM, Heimall J, Freeman AF, Hsu AP, Brittain E, Brenchley JM, et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity (2011) 35:806-18. doi:10.1016/j.immuni.2011.09.016
57. Meloni A, Willcox N, Meager A, Atzeni M, Wolff AS, Husebye ES, et al. Autoimmune polyendocrine syndrome type 1: an extensive longitudinal study in Sardinian patients. J Clin Endocrinol Metab (2012) 97:1114-24. doi:10.1210/jc.2011-2461
58. Dong C. Th17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol (2008) 8:337-48. doi:10.1038/nri2295
59. Gaffen SL, Jain R, Garg AV, Cua DJ. IL-23-IL-17 immune axis: discovery, mechanistic understanding, and clinical testing. Nat Rev Immunol (2014) 14:585-600. doi:10.1038/nri3707
60. Eyerich E, Eyerich K, Cavani A, Schmidt-Weber C. IL-17 and IL-22: siblings, not twins. Trends Immunol (2010) 31:354-61. doi:10.1016/j.it.2010.06.004
61. Sparber F, LeibundGut-Landmann S. Interleukin 17-mediated host defense against Candida albicans. Pathogens (2015) 4:606-19. doi:10.3390/pathogens4030606
62. Whibley N, Gaffen SL. Brothers in arms: Th17 and Treg responses in Candida albicans immunity. PLoS Pathog (2014) 10:e1004456. doi:10.1371/journal.ppat.1004456
63. Conti HR, Whibley N, Coleman BM, Garg AV, Jillian Jaycox R, Gaffen SL. Signaling through IL-17C/IL-17RE is dispensable for immunity to systemic, oral and cutaneous candidiasis. PLoS One (2015) 10(4):e0122807. eCollection 2015 doi:10.1371/journal.pone.0122807
64. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, et al. IL-22 medicates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med (2008) 14:275-81. doi:10.1038/nm1710
65. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis (2004) 190:624-31. doi:10.1086/422329
66. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med (2002) 347:1151-60. doi:10.1056/NEJMoa021481
67. Kao CY, Chen Y, Thai P, Wachi S, Kim C, Tam L, et al. IL-17 markedly up-regulates betadefensin-2 expression in human airway epithelium via JAK and NF-kB signaling pathways. J Immunol (2004) 173:3482-91. doi:10.4049/jimmunol.173.5.3482
68. Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, et al. A critical role for IL-21 in regulating immunoglobulin production. Science (2002) 298:1630-4. doi:10.1126/science.1077002
69. Avery DT, Ma CS, Bryant VL, Santner-Nanan B, Nanan R, Wong M, et al. STAT3 is required for IL-21 induced secretion of IgE from human naive B cells. Blood (2008) 112:1784-93. doi:10.1182/blood-2008-02-142745
70. Shang XZ, Ma KY, Radewonuk J, Li J, Song XY, Griswold DE, et al. IgE isotype switch and IgE production are enhanced in IL-21-deficient but not IFN-gamma-deficient mice in a Th2-biased response. Cell Immunol (2006) 241:66-74. doi:10.1016/j.cellimm.2006.07.011
71. Renner ED, Puck JM, Holland SM, Schmitt M, Weiss M, Frosch M, et al. Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J Pediatr (2004) 144:93-9. doi:10.1016/S0022-3476(03)00449-9
72. Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, Kreins AY, Grant AV, Abel L, et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr (2012) 160:1055-7. doi:10.1016/j.jpeds.2012.01.056
73. Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med (2009) 361:2046-55. doi:10.1056/NEJMoa0905506
74. Jabara HH, McDonald DR, Janssen E, Massaad MJ, Ramesh N, Borzutzky A, et al. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nat Immunol (2012) 13:612-20. doi:10.1038/ni.2305
75. Randall KL, Chan SS, Ma CS, Fung I, Mei Y, Yabas M, et al. DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. J Exp Med (2011) 208:2305-20. doi:10.1084/jem.20110345
76. Davi SD, Schaller J, Wedgwood RJ. Job's syndrome. Recurrent, "cold", staphylococcal abscesses. Lancet (1966) 1:1013-5.
77. Freeman AF, Holland SM. The hyper-IgE syndromes. Immunol Allergy Clin North Am (2008) 28:277-91. doi:10.1016/j.iac.2008.01.005
78. Szczawinska-Poplonyk A, Kycler Z, Pietrucha B, Heropolitanska-Pliszka E, Breborowicz A, Gerreth K. The hyperimmunoglobulin E syndrome-clinical manifestation diversity in primary immune deficiency. Orphanet J Rare Dis (2011) 6:76. doi:10.1186/1750-1172-6-76
79. Randall KL, Lambe T, Goodnow CC, Cornall RJ. The essential role of DOCK8 in humoral immunity. Dis Markers (2010) 29:141-50. doi:10.3233/DMA-2010-0739
80. Su HC. DOCK8 (dedicator of cytokinesis 8) deficiency. Curr Opin Allergy Clin Immunol (2010) 10:515-20. doi:10.1097/ACI.0b013e32833fd718
81. Zhang Y. Autosomal recessive PGM3 mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. J Allergy Clin Immunol (2014) 133:1400-9. doi:10.1016/j.jaci.2014.02.013
82. Avery DT, Deenick EK, Ma CS, Suryani S, Simpson N, Chew GY, et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med (2010) 207:155-71. doi:10.1084/jem.20091706
83. Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity (2012) 36:515-28. doi:10.1016/j.immuni.2012.03.016
84. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med (2013) 368:161-70. doi:10.1056/NEJMra1202117
85. Forte G, Sorrentino R, Montinaro A, Luciano A, Adcock IM, Maiolino P, et al. Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol (2012) 189:2226-33. doi:10.4049/jimmunol.1200744
86. Sorrentino R, Morello S, Forte G, Montinaro A, De Vita G, Luciano AP, et al. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am J Respir Crit Care Med (2011) 183:1369-79. doi:10.1164/rccm.201010-1738OC
87. Maródi L. Mucocutaneous candidiasis. In: Sullivan KE, Stiehm RE, editors. Stiehm's Immunodeficiencies. Amsterdam: Elsevier Inc. (2014). p. 775-802.
88. Mogensen TH. STAT3 and the Hyper-IgE syndrome: clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. JAKSTAT (2013) 2:e23435. doi:10.4161/jkst.23435
89. Ouederni M, Sanal O, Ikinciogullari A, Ouederni M, Sanal O, Ikinciogullari A, et al. Clinical features of Candidiasis in patients with inherited interleukin 12 receptor β1 deficiency. Clin Infect Dis (2014) 58:204-13. doi:10.1093/cid/cit722
90. Prando C, Samarina A, Bustamante J, Boisson-Dupuis S, Cobat A, Picard C, et al. Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from30 kindreds. Medicine (Baltimore) (2013) 92:109-22. doi:10.1097/MD.0b013e31828a01f9
91. Puel A, Cypowyj S, Maródi L, Abel L, Picard C, Casanova JL. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol (2012) 12:616-22. doi:10.1097/ACI.0b013e328358cc0b
92. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science (2011) 332:65-8. doi:10.1126/science.1200439
93. Zheng J, van de Veerdonk FL, Crossland KL, Smeekens SP, Chan CM, Shehri TA, et al. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC). Eur J Immunol (2015) 45:2834-46. doi:10.1002/eji.201445344
94. Mizoguchi Y, Tsumura M, Okada S, Hirata O, Minegishi S, Hyakuna N, et al. STAT1 gain-of-function in patients with chronic mucocutaneous candidiasis can be detected by the excessive phosphorylation of STAT1 in peripheral blood monocytes. Blood (2014) 124:4111.
95. Delsing CE, Bleeker-Rovers CP, van de Veerdonk FL, Tol JJ, van der Meer WM, Kullberg BJ, et al. Association of esophageal candidiasis and squamous cell carcinoma. Med Mycol Case Rep (2012) 1:5-8. doi:10.1016/j.mmcr.2012.02.003
96. Cypowyj S, Picard C, Maródi L, Casanova JL, Puel A. Immunity to infection in IL-17-deficient mice and humans. Eur J Immunol (2012) 42:2246-54. doi:10.1002/eji.201242605
97. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol (2009) 27:485-517. doi:10.1146/annurev.immunol.021908.132710
98. Maródi L, Cypowyj S, Toth B, Chernyshova L, Puel A, Casanova JL. Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species. J Allergy Clin Immunol (2012) 130:1019-27. doi:10.1016/j.jaci.2012.09.011
99. Maródi L, Cypowyj S, Casanova JL, Puel A. The role of human IL-17 immunity in fungal disease. Curr Fungal Infect Rep (2013) 7:132-7. doi:10.1007/s12281-013-0131-4
100. Grimbacher B, Holland SM, Puck JM. Hyper-IgE syndromes. Immunol Rev (2005) 203:244-50. doi:10.1111/j.0105-2896.2005.00228.x
101. Rosa DD, Pasqualotto AC, Denning DW. Chronic mucocutaneous candidiasis and oesophageal cancer. Med Mycol (2008) 46:85-91. doi:10.1080/13693780701616023
102. Goransdotter EK, Fadeel B, Nilsson-Ardnor S, Söderhäll C, Samuelsson A, Janka G, et al. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis. Am J Hum Genet (2001) 68:590-7. doi:10.1086/318796
103. Trizzino A, Zur Stadt U, Ueda I, Risma K, Janka G, Ishii E, et al. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations. J Med Genet (2008) 45:15-21. doi:10.1136/jmg.2007.052670
104. Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood (2002) 99:61-6. doi:10.1182/blood.V99.1.61
105. Feldmann J, Le Deist F, Ouachee-Chardin M, Certain S, Alexander S, Quartier P, et al. Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. Br J Haematol (2002) 117:965-72. doi:10.1046/j.1365-2141.2002.03534.x
106. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med (2012) 63:233-46. doi:10.1146/annurev-med-041610-134208
107. Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol (2006) 6:940-52. doi:10.1038/nri1983
108. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science (1999) 286:1957-9. doi:10.1126/science.286.5446.1957
109. Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood (2011) 118:5794-8. doi:10.1182/blood-2011-07-370148
110. Zhang K, Chandrakasan S, Chapman H, Valencia CA, Husami A, Kissell D, et al. Synergistic defects of different molecules in the cytotoxic pathway lead to clinical familial hemophagocytic lymphohistiocytosis. Blood (2014) 124:1331-4. doi:10.1182/blood-2014-05-573105
111. Mhatre S, Madkaikar M, Desai M, Ghosh K. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis (FHL) patients in India. Blood Cells Mol Dis (2015) 54:250-7. doi:10.1016/j.bcmd.2014.11.023
112. Henter JI, Elinder G, Söder O, Hansson M, Andersson B, Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood (1991) 78:2918-22.
113. Komp DM, McNamara J, Buckley P. Elevated soluble interleukin-2 receptor in childhood hemophagocytic syndromes. Blood (1989) 73:2128-32.
114. Imashuku S, Ikushima S, Esumi N, Todo S, Saito M. Serum levels of interferon-gamma, cytotoxic factor and soluble interleukin-2 receptor in childhood hemophagocytic syndromes. Leuk Lymphoma (1991) 3:287-92. doi:10.3109/10428199109107916
115. Osugi Y, Hara J, Tagawa S, Takai K, Hosoi G, Matsuda Y, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood (1997) 89:4100-3.
116. Neven B, Mamessier E, Bruneau J, Kaltenbach S, Kotlarz D, Suarez F, et al. A Mendelian predisposition to B cell lymphoma caused by IL-10R deficiency. Blood (2013) 122:3713-22. doi:10.1182/blood-2013-06-508267
117. Filipovich AH, Mathur A, Kamat D, Kersey JH, Shapiro RS. Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency (1994) 5:91-112.
118. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol (2005) 94:S1-63. doi:10.1016/S1081-1206(10)61142-8
119. Schroeder HW Jr, Zhu ZB, March RE, Campbell RD, Berney SM, Nedospasov SA, et al. Susceptibility locus for IgA deficiency and common variable immunodeficiency in the HLA-DR3, 2B8, 2A1 haplotypes. Mol Med (1998) 4:72-86.
120. Aghamohammadi A, Mohammadi J, Parvaneh N, Rezaei N, Moin M, Espanol T, et al. Progression of selective IgA deficiency to common variable immunodeficiency. Int Arch Allergy Immunol (2008) 147:87-92. doi:10.1159/000135694
121. Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A, et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol (1997) 158:977-83.
122. Wobser M, Kerstan A, Kneitz H, Goebeler M, Kunzmann V, Rosenwald A, et al. Primary cutaneous marginal zone lymphoma with sequential development of nodal marginal zone lymphoma in a patient with selective immunoglobulin A deficiency. J Cutan Pathol (2013) 40:1035-41. doi:10.1111/cup.12230
123. Ott MM, Ott G, Klinker H, Trunk MJ, Katzenberger T, Müller-Hermelink HK. Abdominal T-cell non-Hodgkin's lymphoma of the gamma/delta type in a patient with selective immunoglobulin A deficiency. Am J Surg Pathol (1998) 22:500-6. doi:10.1097/00000478-199804000-00017
124. Gross TG, Shiramizu B. Lymphoproliferative disorders and malignancies related to immunodeficiencies. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams & Wilkins (2006). p. 748-67.
125. de Miranda NF, Björkman A, Pan-Hammarström Q. DNA repair: the link between primary immunodeficiency and cancer. Ann N Y Acad Sci (2011) 1246:50-63. doi:10.1111/j.1749-6632.2011.06322.x
126. Taylor AMR, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood (1996) 87:423-38.
127. Sandoval C, Swift M. Hodgkin disease in ataxis-telangiectasia patients with poor outcomes. Med Pediatr Oncol (2003) 40:162-6. doi:10.1002/mpo.10251
128. Heintz N. Ataxia telangiectasia: cell signaling, cell death and the cell cycle. Curr Opin Neurol (1996) 9:137-40. doi:10.1097/00019052-199604000-00014
129. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst (1986) 77:89-92.
130. Dembowska-Baginska B, Perek D, Brozyna A, Wakulinska A, Olczak-Kowalczyk D, Gladkowska-Dura M, et al. Non-Hodgkin lymphoma (NHL) in children with Nijmegen breakage syndrome (NBS). Pediatr Blood Cancer (2009) 52:186-90. doi:10.1002/pbc.21789
131. Online Mendelian Inheritance in Man (OMIM) database. Johns Hopkins University. Nijmegen Breakage Syndrome. (2009). Available from: http://www.omim.org/entry/613078
132. van der Burgt I, Chrzanowska KH, Smeets D, Weemaes C. Nijmegen breakage syndrome. J Med Genet (1996) 33:153-6. doi:10.1136/jmg.33.2.153
133. Massaad MJ, Ramesh N, Geha RS. Wiskott-Aldrich syndrome: a comprehensive review. Ann N Y Acad Sci (2013) 1285:26-43. doi:10.1111/nyas.12049
134. Cotelingam JD, Witebsky FG, Hsu SM, Blaese RM, Jaffe ES. Malignant lymphoma in patients with the Wiskott-Aldrich syndrome. Cancer Invest (1985) 3:515-22. doi:10.3109/07357908509039813
135. Kroft SH, Finn WG, Singleton TP, Ross CW, Sheldon S, Schnitzer B. Follicular large cell lymphoma with immunoblastic features in a child with Wiskott-Aldrich syndrome: an unusual immunodeficiency-related neoplasm not associated with Epstein-Barr virus. Am J Clin Pathol (1998) 110:95-9. doi:10.1093/ajcp/110.1.95
136. Singh VK, Newmana VL, Seed TM. Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): a review. Cytokine (2015) 71:22-37. doi:10.1016/j.cyto.2014.08.003
137. Bresnick EH, Katsumura KR, Lee HY, Johnson KD, Perkins AS. Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies. Nucleic Acids Res (2012) 40:5819-31. doi:10.1093/nar/gks281
138. Tang X, Lasbury ME, Davidson DD, Bartlett MS, Smith JW, Lee CH. Downregulation of GATA-2 transcription during Pneumocystis carinii infection. Infect Immun (2015) 68:4720-4. doi:10.1128/IAI.68.8.4720-4724.2000
139. Lasbury ME, Tang X, Durant PJ, Lee CH. Effect of transcription factor GATA-2 on phagocytic activity of alveolar macrophages from Pneumocystis carinii-infected hosts. Infect Immun (2003) 71:4943-52. doi:10.1128/IAI.71.9.4943-4952.2003
140. Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood (2014) 123:809-21. doi:10.1182/blood-2013-07-515528
141. Welte K, Zeidler C. Severe congenital neutropenia. Hematol Oncol Clin North Am (2009) 23:307-20. doi:10.1016/j.hoc.2009.01.013
142. Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey. Blood (2007) 109:93-9. doi:10.1182/blood-2006-02-004275
143. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res (1970) 13:1-27. doi:10.1159/000386035
144. Umaimainthan P, Rickinson AB. Primary immunodeficiencies and the control of Epstein-Barr virus infection. Ann N Y Acad Sci (2015) 1356:22-44. doi:10.1111/nyas.12937
145. Jonkman-Berk BM, van den Berg JM, Ten Berge IJ, Bredius RG, Driessen GJ, Dalm VA, et al. Primary immunodeficiencies in the Netherlands: national patient data demonstrate the increased risk of malignancy. Clin Immunol (2015) 156:154-62. doi:10.1016/j.clim.2014.10.003
146. Kersey JH, Shapiro RS, Filipovich AH. Relationship of immunodeficiency to lymphoid malignancy. Pediatr Infect Dis J (1988) 7:S10-2. doi:10.1097/00006454-198805001-00003
147. Filipovich AH, Mathur A, Kamat D, Shapiro RS. Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res (1992) 52:5465-7.
148. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc (1969) 1:106-12.
149. Latour S, Aguilar C. XIAP deficiency syndrome in humans. Semin Cell Dev Biol (2015) 39:115-23. doi:10.1016/j.semcdb.2015.01.015
150. Krieg A, Correa RG, Garrison JB, Le Negrate G, Welsh K, Huang Z, et al. XIAP mediates NOD signaling via interaction with RIP2. Proc Natl Acad Sci U S A (2009) 106:14524-9. doi:10.1073/pnas.0907131106
151. Damgaard RB, Nachbur U, Yabal M, Wong WW, Fiil BK, Kastirr M, et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell (2012) 46:1-13. doi:10.1016/j.molcel.2012.04.014
152. Damgaard RB, Fiil BK, Speckmann C, Yabal M, Stadt UZ, Bekker-Jensen S, et al. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol Med (2013) 5:1278-95. doi:10.1002/emmm.201303090
153. Hsieh WC, Chuang YT, Chiang IH, Hsu SC, Miaw SC, Lai MZ. Inability to resolve specific infection generates innate immunodeficiency syndrome in Xiap-/-mice. Blood (2014) 124:2847-57. doi:10.1182/blood-2014-03-564609
154. Oertel S, Reiss H. Immunosurveillance, Immunodeficiency and Lymphoproliferations. Heidelberg: Springer (2002). 159 p.
155. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest (2007) 117:1137-46. doi:10.1172/JCI31405
156. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 410:1107-11. doi:10.1038/35074122
157. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gamma delta T cells. Science (2001) 294:605-9. doi:10.1126/science.1063916
158. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 6:722-9. doi:10.1038/ni1213
159. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferongamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 95:7556-61. doi:10.1073/pnas.95.13.7556
160. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 196:129-34. doi:10.1084/jem.20020063
161. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med (2000) 192:755-60. doi:10.1084/jem.192.5.755
162. Thomas L. Discussion. In: Lawrence HS, editor. Cellular and Humoral Aspects of the Hypersensitive States. New York: Hoeber-Harper (1959). p. 529-32.
163. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet (1978) 2:1323-7. doi:10.1016/S0140-6736(78)91970-0
164. Hoover R, Fraumeni JF. Risk of cancer in renal-transplant recipients. Lancet (1973) 2:55-7. doi:10.1016/S0140-6736(73)93256-X
165. List AF, Greco FA, Vogler LB. Lympho proliferative diseases in immuno-compromised hosts: the role of Epstein-Barr virus. J Clin Oncol (1987) 5:1673-89.
166. Clifford GM, Polesel J, Rickenbach M, DalMaso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst (2005) 97:425-32. doi:10.1093/jnci/dji072
167. Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett (2014) 588:368-76. doi:10.1016/j.febslet.2013.10.015
168. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 285:727-9. doi:10.1126/science.285.5428.727
169. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A (1996) 93:12445-50. doi:10.1073/pnas.93.22.12445
170. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005) 436:1186-90. doi:10.1038/nature03884
171. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A (1999) 96:6879-84. doi:10.1073/pnas.96.12.6879
172. Vantourout P, Willcox C, Turner A, Swanson CM, Haque Y, Sobolev O, et al. Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway. Sci Transl Med (2014) 6:231-49. doi:10.1126/scitranslmed.3007579
173. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity (2008) 28:571-80. doi:10.1016/j.immuni.2008.02.016
174. Chen D, Juko-Pecirep I, Hammer J, Ivansson E, Enroth S, Gustavsson I, et al. Genome-wide association study of susceptibility loci for cervical cancer. J Natl Cancer Inst (2013) 105:624-33. doi:10.1093/jnci/djt051
175. Melum E, Karlsen TH, Schrumpf E, Bergquist A, Thorsby E, Boberg KM, et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology (2008) 47:90-6. doi:10.1002/hep.21964
176. Wheat WH, Cool CD, Morimoto Y, Rai PR, Kirkpatrick CH, Lindenbaum BA, et al. Possible role of human herpes virus 8 in the lymphoproliferative disorders in common variable immunodeficiency. J Exp Med (2005) 202:479-84. doi:10.1084/jem.20050381
177. Raeiszadeh M, Kopycinski J, Paston SJ, Diss T, Lowdell M, Hardy GAD, et al. The T cell response to persistent herpes virus infections in common variable immunodeficiency. Clin Exp Immunol (2006) 146:234-42. doi:10.1111/j.1365-2249.2006.03209.x
178. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol (2007) 38:1293-304. doi:10.1016/j.humpath.2007.05.020
179. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science (2014) 343:152-7. doi:10.1126/science.1246886
180. Filipovich AH, Heinitz KJ, Robison LL, Frizzera G. The Immunodeficiency Cancer Registry. A research resource. Am J Pediatr Hematol Oncol (1987) 9:183-4. doi:10.1097/00043426-198722000-00017
181. A Randomized, Controlled Clinical Trial Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. N Engl J Med (1988) 319:902-7.
182. Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood (1989) 73:366-8.
183. Gamm H, Huber C, Chapel H, Lee M, Ries F, Dicato MA. Intravenous immune globulin in chronic lymphocytic leukemia. Clin Exp Immunol (1994) 97:17-20.
184. Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoira L, et al. Prophylaxis against infections with low dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica (1996) 81:121-6.